AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30864756 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational health programs
Number of subjects: 908
Study 26483255 — intervention group
Group type: EXPERIMENTAL
Intervention: MBDA scores (scale 1‐100)
Number of subjects: 94
Study 26483255 — intervention group
Group type: EXPERIMENTAL
Intervention: ACPA status
Number of subjects: 94
Study 24760259 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose vitamin D supplementation (5,000 IU daily)
Number of subjects: 179
Study 24760259 — intervention group
Group type: COMPARATOR
Intervention: Low-dose vitamin D supplementation (400 IU daily)
Number of subjects: 179
Study 24047015 — intervention group
Group type: EXPERIMENTAL
Intervention: PGE2 vaginal gel
Number of subjects: 72
Study 24047015 — intervention group
Group type: COMPARATOR
Intervention: iv oxytocin
Number of subjects: 72
Study 19295225 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimony 6x
Number of subjects: 30
Study 19295225 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 17264104 — intervention group
Group type: EXPERIMENTAL
Intervention: Group tai chi sessions (40 min/session, 3 times a week for 6 weeks) followed by home-based tai chi training (6 weeks)
Number of subjects: 41
Study 17264104 — intervention group
Group type: COMPARATOR
Intervention: Attention control group (health lectures for 6 weeks)
Number of subjects: 41
Study 17264104 — intervention group
Group type: EXPERIMENTAL
Intervention: Group tai chi sessions
Number of subjects: 41
Study 15650978 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic epidural analgesia (TEA)
Number of subjects: 163
Study 15650978 — intervention group
Group type: EXPERIMENTAL
Intervention: TEA and amiodarone
Number of subjects: 163
Study 15650978 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 163
Study 15650978 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 163
Study 11239859 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical povidone-iodine (5%) solution applied 10 and 5 minutes before surgery and vancomycin (20 microg/ml) in the irrigating fluid
Number of subjects: 400
Study 11239859 — intervention group
Group type: EXPERIMENTAL
Intervention: Vancomycin (20 microg/ml) in the irrigating fluid
Number of subjects: 400
Study 11239859 — intervention group
Group type: COMPARATOR
Intervention: Topical placebo solution and irrigating fluid only without antibiotics
Number of subjects: 400
Study 9651405 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg of elemental zinc daily for 6 months
Number of subjects: 609
Study 9651405 — intervention group
Group type: COMPARATOR
Intervention: Control group (no zinc supplementation)
Number of subjects: 609
Study 9651405 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation
Number of subjects: 609
Study 9828781 — intervention group
Group type: EXPERIMENTAL
Intervention: Early surgery
Number of subjects: 0
Study 9828781 — intervention group
Group type: COMPARATOR
Intervention: Late surgery
Number of subjects: 0
Study 2198296 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem, an imidazopyridine hypnotic compound
Number of subjects: 0
Study 714200 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthiazide (500 mg twice a day)
Number of subjects: 15
Study 714200 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthiazide (500 mg twice a day) + Propranolol (10‐‐20 mg 4 times a day)
Number of subjects: 15
Study 714200 — intervention group
Group type: COMPARATOR
Intervention: Control (no propranolol)
Number of subjects: 15
Study 31868538 — intervention group
Group type: EXPERIMENTAL
Intervention: Associative learning
Number of subjects: 0
Study 31868538 — intervention group
Group type: EXPERIMENTAL
Intervention: Environmental patterns
Number of subjects: 0
Study 31868538 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrinsic value system
Number of subjects: 0
Study 31344751 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-based treatment for paediatric obesity (FBT-PO)
Number of subjects: 77
Study 31344751 — intervention group
Group type: COMPARATOR
Intervention: Nutrition education counselling (NEC)
Number of subjects: 77
Study 28079396 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine supplementation for 7 days
Number of subjects: 67
Study 28079396 — intervention group
Group type: COMPARATOR
Intervention: Placebo supplementation for 7 days
Number of subjects: 67
Study 25684604 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide 0.6 mg once daily
Number of subjects: 605
Study 25684604 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide 1.2 mg once daily
Number of subjects: 605
Study 25684604 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide 1.8 mg once daily
Number of subjects: 605
Study 25684604 — intervention group
Group type: COMPARATOR
Intervention: Reference subject (67 kg)
Number of subjects: 605
Study 25684604 — intervention group
Group type: COMPARATOR
Intervention: Gender, age, and country
Number of subjects: 605
Study 23642977 — intervention group
Group type: EXPERIMENTAL
Intervention: Psycho-education along with pharmacotherapy treatment
Number of subjects: 108
Study 23642977 — intervention group
Group type: COMPARATOR
Intervention: Pharmacotherapy alone
Number of subjects: 108
Study 21285531 — intervention group
Group type: EXPERIMENTAL
Intervention: MF59®-adjuvanted formulation containing 7.5 μg antigen
Number of subjects: 392
Study 21285531 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-adjuvanted formulations containing 15 or 30 μg antigen
Number of subjects: 392
Study 21285531 — intervention group
Group type: EXPERIMENTAL
Intervention: MF59®-adjuvanted vaccine
Number of subjects: 392
Study 21285531 — intervention group
Group type: EXPERIMENTAL
Intervention: All vaccines (including both adjuvanted and non-adjuvanted)
Number of subjects: 392
Study 19856243 — intervention group
Group type: EXPERIMENTAL
Intervention: Atosiban
Number of subjects: 0
Study 19856243 — intervention group
Group type: COMPARATOR
Intervention: Fenoterol (pulsatile administration)
Number of subjects: 0
Study 16886936 — intervention group
Group type: EXPERIMENTAL
Intervention: VIP (8 pmol/kg per min)
Number of subjects: 12
Study 16886936 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% saline)
Number of subjects: 12
Study 14760339 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mL of red wine
Number of subjects: 16
Study 14760339 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mL of dealcoholized red wine
Number of subjects: 16
Study 14760339 — intervention group
Group type: COMPARATOR
Intervention: 1 cigarette (smoking only)
Number of subjects: 16
Study 11740417 — intervention group
Group type: EXPERIMENTAL
Intervention: Unfractioned heparin (UFH) - 5000 units s.c. x 3 daily
Number of subjects: 50
Study 11740417 — intervention group
Group type: COMPARATOR
Intervention: Low molecular weight heparin (LMWH) - calcium nadroparin, single daily dose of 0.3 ml s.c.
Number of subjects: 50
Study 8976223 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lidocaine jelly
Number of subjects: 179
Study 8976223 — intervention group
Group type: COMPARATOR
Intervention: Plain lubricant
Number of subjects: 179
Study 8116325 — intervention group
Group type: EXPERIMENTAL
Intervention: Propacetamol 2 g every 6 hours for 24 hours
Number of subjects: 40
Study 8116325 — intervention group
Group type: COMPARATOR
Intervention: Saline every 6 hours for 24 hours (Control)
Number of subjects: 40
Study 8116325 — intervention group
Group type: EXPERIMENTAL
Intervention: Piritramide administration in both groups
Number of subjects: 40
Study 8116325 — intervention group
Group type: EXPERIMENTAL
Intervention: Propacetamol given from 12 hours after surgery
Number of subjects: 40
Study 3311480 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortisone treatment (50 mg orally twice daily for 4 days)
Number of subjects: 8
Study 3311480 — intervention group
Group type: COMPARATOR
Intervention: Control (absence of any medication)
Number of subjects: 8
Study 29125901 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (HCQ) 400 mg once a day
Number of subjects: 196
Study 29125901 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 196
Study 28528120 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 1 Diabetes Mellitus (DM)
Number of subjects: 56
Study 28528120 — intervention group
Group type: COMPARATOR
Intervention: Healthy children (Control)
Number of subjects: 56
Study 26537948 — intervention group
Group type: EXPERIMENTAL
Intervention: Septoplasty (with or without concurrent turbinate surgery)
Number of subjects: 200
Study 26537948 — intervention group
Group type: COMPARATOR
Intervention: Non-surgical management (watchful waiting strategy)
Number of subjects: 200
Study 22643040 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic assisted laparoscopic abdominal sacrocolpopexy (RASC)
Number of subjects: 64
Study 22643040 — intervention group
Group type: COMPARATOR
Intervention: Pure laparoscopic abdominal sacrocolpopexy (LASC)
Number of subjects: 64
Study 22643040 — intervention group
Group type: EXPERIMENTAL
Intervention: RASC
Number of subjects: 64
Study 22643040 — intervention group
Group type: COMPARATOR
Intervention: LASC
Number of subjects: 64
Study 20395857 — intervention group
Group type: EXPERIMENTAL
Intervention: Parathyroidectomy
Number of subjects: 18
Study 20395857 — intervention group
Group type: COMPARATOR
Intervention: Control (observed for 6 months)
Number of subjects: 18
Study 18545210 — intervention group
Group type: COMPARATOR
Intervention: Circuit training (S)
Number of subjects: 48
Study 18545210 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance before circuit training (E+S)
Number of subjects: 48
Study 18545210 — intervention group
Group type: EXPERIMENTAL
Intervention: Circuit before endurance training (S+E)
Number of subjects: 48
Study 18545210 — intervention group
Group type: COMPARATOR
Intervention: No training (C)
Number of subjects: 48
Study 18545210 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance training (E)
Number of subjects: 48
Study 18545210 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance-type circuit training (weeks 1-6)
Number of subjects: 48
Study 18545210 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance-type circuit training (weeks 7-12)
Number of subjects: 48
Study 15961424 — intervention group
Group type: EXPERIMENTAL
Intervention: Air dive at 280 kPa for 80 min
Number of subjects: 21
Study 15961424 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen breathing (60% oxygen) at 280 kPa for 80 min
Number of subjects: 21
Study 15961424 — intervention group
Group type: COMPARATOR
Intervention: Normal controls (no diving)
Number of subjects: 21
Study 12714348 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (500 microg)
Number of subjects: 18
Study 12714348 — intervention group
Group type: COMPARATOR
Intervention: Placebo nebulization
Number of subjects: 18
Study 10482088 — intervention group
Group type: EXPERIMENTAL
Intervention: Brimonidine 0.2% topically twice daily for 29 days
Number of subjects: 28
Study 10482088 — intervention group
Group type: COMPARATOR
Intervention: Vehicle treatment (control)
Number of subjects: 28
Study 8735778 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g of vitamin C for 14 days
Number of subjects: 16
Study 8735778 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 14 days
Number of subjects: 16
Study 1751367 — intervention group
Group type: EXPERIMENTAL
Intervention: Sudan Black positivity (SB positivity)
Number of subjects: 1386
Study 1751367 — intervention group
Group type: EXPERIMENTAL
Intervention: Low complement of maturing granulocytes
Number of subjects: 1386
Study 1751367 — intervention group
Group type: EXPERIMENTAL
Intervention: High percentage of blasts
Number of subjects: 1386
Study 1751367 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute promyelocytic leukaemia (FAB M3)
Number of subjects: 1386
Study 1751367 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple lineage leukaemias with megakaryocytic and/or erythroid involvement
Number of subjects: 1386
Study 1751367 — intervention group
Group type: EXPERIMENTAL
Intervention: Percentage SB positivity
Number of subjects: 1386
Study 1751367 — intervention group
Group type: EXPERIMENTAL
Intervention: SB positivity
Number of subjects: 1386
Study 7038076 — intervention group
Group type: EXPERIMENTAL
Intervention: Exchange transfusion
Number of subjects: 33
Study 7038076 — intervention group
Group type: EXPERIMENTAL
Intervention: Administration of fresh-frozen plasma and platelets
Number of subjects: 33
Study 7038076 — intervention group
Group type: COMPARATOR
Intervention: Control (no therapy directed specifically at the coagulopathy)
Number of subjects: 33
Study 31935272 — intervention group
Group type: EXPERIMENTAL
Intervention: Food insecurity (mild, moderate, severe)
Number of subjects: 417
Study 31935272 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower dietary diversity
Number of subjects: 417
Study 31935272 — intervention group
Group type: EXPERIMENTAL
Intervention: Unemployment of participants or spouses
Number of subjects: 417
Study 31935272 — intervention group
Group type: EXPERIMENTAL
Intervention: Owning cultivable land
Number of subjects: 417
Study 31935272 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants' unemployment status
Number of subjects: 417
Study 30909877 — intervention group
Group type: EXPERIMENTAL
Intervention: Temperature at +22 °C with brisk walking for 30 min
Number of subjects: 18
Study 30909877 — intervention group
Group type: EXPERIMENTAL
Intervention: Temperature at -15 °C with brisk walking for 30 min
Number of subjects: 18
Study 30909877 — intervention group
Group type: EXPERIMENTAL
Intervention: Temperature at +22 °C at rest for 30 min
Number of subjects: 18
Study 30909877 — intervention group
Group type: EXPERIMENTAL
Intervention: Temperature at -15 °C at rest for 30 min
Number of subjects: 18
Study 29084597 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual community of practice for primary healthcare professionals for 12 months
Number of subjects: 270
Study 29084597 — intervention group
Group type: COMPARATOR
Intervention: Usual training
Number of subjects: 270
Study 29084597 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual community of practice
Number of subjects: 270
Study 24756025 — intervention group
Group type: EXPERIMENTAL
Intervention: BCI-Manus therapy
Number of subjects: 26
Study 24756025 — intervention group
Group type: COMPARATOR
Intervention: Manus therapy
Number of subjects: 26
Study 24245880 — intervention group
Group type: EXPERIMENTAL
Intervention: Restylane Vital® with NAHSA injector
Number of subjects: 10
Study 24245880 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated side)
Number of subjects: 10
Study 22955227 — intervention group
Group type: EXPERIMENTAL
Intervention: Late CNI withdrawal
Number of subjects: 108
Study 22955227 — intervention group
Group type: COMPARATOR
Intervention: MMF withdrawal
Number of subjects: 108
Study 19838098 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 10 mg/day
Number of subjects: 88
Study 19838098 — intervention group
Group type: COMPARATOR
Intervention: Pravastatin 40 mg/day
Number of subjects: 88
Study 19838098 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 88
Study 17624196 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoricoxib (90 mg, tablet)
Number of subjects: 220
Study 17624196 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 220
Study 16317669 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA) 1 g/day for three weeks
Number of subjects: 130
Study 16317669 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 12 mg/day for 1 week and placebo during weeks 2 and 3
Number of subjects: 130
Study 16317669 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 3 weeks
Number of subjects: 130
Study 14569803 — intervention group
Group type: EXPERIMENTAL
Intervention: ASCUS management strategies
Number of subjects: 2000000
Study 14569803 — intervention group
Group type: EXPERIMENTAL
Intervention: Bethesda System 2001 Workshop recommendations
Number of subjects: 2000000
Study 9593551 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF)
Number of subjects: 0
Study 7645522 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem plus trimetazidine (diltiazem 60 mg three times daily and trimetazidine 20 mg three times daily)
Number of subjects: 67
Study 7645522 — intervention group
Group type: COMPARATOR
Intervention: Diltiazem plus placebo
Number of subjects: 67
Study 2142741 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous thrombolytic therapy (tissue plasminogen activator)
Number of subjects: 7
Study 2142741 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous thrombolytic therapy (streptokinase)
Number of subjects: 7
Study 2142741 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined trials of intravenous thrombolysis
Number of subjects: 7
Study 2142741 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (control)
Number of subjects: 7
Study 277563 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini-lecture
Number of subjects: 12
Study 277563 — intervention group
Group type: COMPARATOR
Intervention: Role-playing
Number of subjects: 12
Study 31100455 — intervention group
Group type: EXPERIMENTAL
Intervention: EPIT with Viaskin milk
Number of subjects: 20
Study 31100455 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 31100455 — intervention group
Group type: EXPERIMENTAL
Intervention: EPIT with Viaskin milk (open-label phase)
Number of subjects: 20
Study 31201564 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound measuring system
Number of subjects: 31
Study 28891839 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 44
Study 28891839 — intervention group
Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 44
Study 25647646 — intervention group
Group type: EXPERIMENTAL
Intervention: Sprint Interval Training (SIT) - 3-8 sprints at maximal intensity, 3 times a week for 4 weeks
Number of subjects: 30
Study 25647646 — intervention group
Group type: EXPERIMENTAL
Intervention: Sprint Interval Training (SIT)
Number of subjects: 30
Study 25647646 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study 23339726 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination aliskiren/valsartan 150/160 mg
Number of subjects: 1143
Study 23339726 — intervention group
Group type: COMPARATOR
Intervention: Valsartan 160 mg monotherapy
Number of subjects: 1143
Study 23339726 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination aliskiren/valsartan
Number of subjects: 1143
Study 23339726 — intervention group
Group type: COMPARATOR
Intervention: Valsartan
Number of subjects: 1143
Study 21401585 — intervention group
Group type: EXPERIMENTAL
Intervention: Constraint‐induced movement therapy (CIMT)
Number of subjects: 63
Study 21401585 — intervention group
Group type: COMPARATOR
Intervention: Bimanual training (BIM)
Number of subjects: 63
Study 18492286 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (provided with additional information regarding the risks of TCS)
Number of subjects: 285
Study 18492286 — intervention group
Group type: COMPARATOR
Intervention: Group B (not provided with additional risk information)
Number of subjects: 285
Study 18492286 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk information provision
Number of subjects: 285
Study 16804292 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole 100 mg/day
Number of subjects: 70
Study 16804292 — intervention group
Group type: COMPARATOR
Intervention: Control group (no ketoconazole)
Number of subjects: 70
Study 12702104 — intervention group
Group type: EXPERIMENTAL
Intervention: GTR + Bio‐Oss (test)
Number of subjects: 18
Study 12702104 — intervention group
Group type: COMPARATOR
Intervention: GTR treatment alone (control)
Number of subjects: 18
Study 10985713 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical repair (31 patients with rupture, 21 had concomitant bypass surgery)
Number of subjects: 939
Study 10985713 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical management (24 patients managed medically)
Number of subjects: 939
Study 10985713 — intervention group
Group type: EXPERIMENTAL
Intervention: In-hospital mortality for patients with VSR
Number of subjects: 939
Study 10985713 — intervention group
Group type: COMPARATOR
Intervention: In-hospital mortality for patients without VSR (control group)
Number of subjects: 939
Study 8623953 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole
Number of subjects: 12
Study 8623953 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole
Number of subjects: 12
Study 8623953 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 1306817 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (N group)
Number of subjects: 1666
Study 1306817 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P group)
Number of subjects: 1666
Study 3935313 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nitroglycerin (5 mg delivered over 24 hours, applied every 48 hours)
Number of subjects: 25
Study 3935313 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 3935313 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nitroglycerin
Number of subjects: 25
Study 30041639 — intervention group
Group type: EXPERIMENTAL
Intervention: Rango Cards, a digital game designed to promote healthy dietary practices.
Number of subjects: 0
Study 30041639 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 0
Study 27263310 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mL normal saline
Number of subjects: 80
Study 27263310 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mL normal saline
Number of subjects: 80
Study 27263310 — intervention group
Group type: COMPARATOR
Intervention: 0 mL normal saline (control group)
Number of subjects: 80
Study 24867930 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet supplemented with 1.09% Gromega
Number of subjects: 0
Study 24867930 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet supplemented with 0.07% zinc sulfate
Number of subjects: 0
Study 24867930 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet supplemented with both Gromega and zinc sulfate
Number of subjects: 0
Study 24867930 — intervention group
Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 0
Study 22233397 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive cortical electrostimulation
Number of subjects: 77
Study 22233397 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77
Study 20381003 — intervention group
Group type: EXPERIMENTAL
Intervention: Medial wedge
Number of subjects: 38